Related Experiment Video
Updated: May 8, 2026
06:19
Intracameral Injection in Rats with Low Risk of Adverse Effects
Published on: May 31, 2024
Intravitreal bevacizumab for posterior capsule neovascularization
Mansour Al-Mohaimeed1, Saeed Al-Gehedan, Hassan Al Dhibi
1College of Medicine, Al-Qassim University, Al-Qassim, P.O. Box 6655, Buraidah 51452, Saudi Arabia.
Summary
Intravitreal bevacizumab (Avastin) effectively treated posterior capsule neovascularization after cataract surgery. This intervention led to rapid visual improvement and regression of neovascularization before YAG capsulotomy.
Area of Science:
- Ophthalmology
- Medical Research
Background:
- Posterior capsule neovascularization (PCN) can occur after cataract surgery, potentially impairing vision.
- Diabetic patients may have an increased risk of developing PCN.
Purpose of the Study:
- To report a case of successful treatment of extensive PCN using intravitreal bevacizumab (Avastin).
- To evaluate the efficacy of bevacizumab in regressing PCN prior to neodymium:YAG capsulotomy.
Main Methods:
- A single intravitreal injection of bevacizumab was administered to a patient with PCN.
- Neodymium:YAG capsulotomy was performed after bevacizumab treatment.
- Clinical observation and visual acuity assessment were conducted.
Main Results:
- Rapid regression of extensive posterior capsule neovascularization was observed within 9 days.
- Significant visual improvement was noted post-intervention.
- Neodymium:YAG capsulotomy was successfully performed without complications.
Conclusions:
- Intravitreal bevacizumab can induce rapid and dramatic regression of posterior capsule neovascularization.
- Bevacizumab is a potential therapeutic option for managing PCN before capsulotomy.
- This approach may improve outcomes for patients experiencing PCN post-cataract surgery.
Related Concept Videos
01:27Open Angle Glaucoma: Treatment
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
01:28Angle Closure Glaucoma: Treatment
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
01:25Glaucoma: Overview
Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...
01:27Diabetic Retinopathy
DefinitionDiabetic retinopathy is a microvascular complication of diabetes affecting the retinal blood vessels.Risk FactorsDiabetic retinopathy is present in almost all individuals with type 1 diabetes and more than 60% of those with type 2 diabetes after two decades of disease.The risk increases with poor glycemic control, hypertension, dyslipidemia, smoking, pregnancy, and puberty.Although cataracts and glaucoma are also more frequent in people with diabetes, retinopathy remains the leading...